Aminoglycosides administration

In the vestibnlar organ, the initial hair cell damage occurs in the apex of the cristae and the striolar regions of the maculi. Hair cell loss then progresses toward the periphery of the vestibular receptor organ with type I hair cells affected earlier than the type 11 hair cells. Vestibular disturbances from systemic aminoglycoside administration present as severe unsteadiness that becomes worse in the dark, bnt an objective clinical assessment is difficult. In contrast to the situation in the cochlea, regeneration of vestibular hair cells has been observed in mammalian species. ... 

Contopoulos-Ioannidis DG et al Extended-interval aminoglycoside administration for children A meta-analysis. Pediatrics... 

The A1555G mutation in the human mitochondrial 12S RNA, which has been associated with hearing loss after aminoglycoside administration (63) and has been rmph-cated in maternally inherited hearing loss in the absence of aminoglycoside exposure in some families, can be identified by a simple and rapid method for large-scale screening that uses one-step multiplex allele-specific PCR (64). 

There is an increase in the urinary output of tubular marker proteins after aminoglycoside administration (102). Determination of A-acetyl-beta-o-glucosaminidase activity in the urine may be used as a screening test to facilitate early detection of the nephrotoxic effect of aminoglycosides (110). Urine chemiluminescence may aid in the detection of neonatal aminoglycoside-induced nephropathy (111). 

In a prospective study on the prevalence of hearing impairment in a neonatal intensive care unit population (a total of 942 neonates were screened), aminoglycoside administration did not seem to be an important risk factor for communication-related hearing impairment (148). In almost all cases, another factor was the more probable cause of the hearing loss (dysmorphism, prenatal rubella or cytomegaly, a positive family history of hearing loss, and severe perinatal and postnatal complications). 

ElittCM, KlepserME, Nightingale CEI,Quintiliani R, Nicolau DP, Pharmacoeconomic impact of once-daily aminoglycoside administration, Pharmacotherapy, 1997 17(4) 810-14. 

Burton ME, Ash CL, Flill DP, Flandy R, Shepherd MD, Vasko MR, A controlled trial of the cost benefit of computerized Bayesian aminoglycoside administration, Clin Pharmacol Ther, 49 685-94. 

Marra F, Partoni N, Jewesson P, Aminoglycoside administrations as a single daily dose An improvement to current practice or a repeat of previous errors Drugs 1996 52 344-376. 

---